Cancer
Malignant Liver Neoplasm
CI-CAN-00003177Explore in graph →
Top-level908 active trials14 approved drugs17 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003177Explore in graph →
Clinical trials
4,126 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (460)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06530251 | A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC) | recruiting | Phase 1 / Phase 2 | 280 | AkesoINDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06885879 | Impact of Radiotherapy on ctDNA in Patients With Hepatocellular Carcinoma | recruiting | — | 15 | Chinese University of Hong KongOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| Evaluation of Stereotactic Body Radiotherapy as a Bridge Therapy for Hepatocellular Carcinoma Patients Enlisted for Liver Transplantation(TRANSRAD-01) |
| recruiting |
| Phase 2 |
| 139 |
| Assistance Publique - Hôpitaux de ParisOTHER |
| 1 |
| Mar 3, 2026 |
| clinicaltrials |
| NCT07295275 | Safety and Efficacy of Transarterial ICG Fluorescence-Guided Laparoscopic Anatomical Liver Resection | recruiting | — | 200 | West China HospitalOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07445412 | Italian Group of Regenerative and Occlusive Worldwide-used Techniques of Hepatic Hypertrophy(I-GROWtoh) | recruiting | — | 2,000 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07447050 | Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial | recruiting | Phase 2 | 24 | University of California, IrvineOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT06789848 | Ligufalimab and Cadonilimab in Advanced Liver Cancers | recruiting | Phase 2 | 64 | University of Texas Southwestern Medical CenterOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07432347 | Decoding Epigenetic Mechanisms Driving Immune Evasion in Liver Cancer With Omics Approaches(DELIVER) | recruiting | — | 270 | Niguarda HospitalOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07436845 | Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy Combined With Targeted and Immunotherapy | recruiting | — | 90 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04134559 | Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma | recruiting | Phase 2 | 18 | Allison O'Neill, MDOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT07429864 | Changes in Bile Acids and Microbiota in Patients With Hepatitis D Treated With Bulvertide(Bio-Delta) | recruiting | — | 20 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT07428356 | Histotripsy for Ablation of Liver Tumours in Asia(HALT) | recruiting | N/A | 40 | National Cancer Centre, SingaporeOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT04907643 | Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes | recruiting | N/A | 360 | Cedars-Sinai Medical CenterOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT05488522 | SBRT With Atezo/Bev for HCC | recruiting | Phase 1 | 18 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT05096715 | Atezolizumab+Bevacizumab+SBRT in Unresectable HCC | recruiting | Phase 1 | 20 | Massachusetts General HospitalOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410494 | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors(SELECT-CAR-NK) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410676 | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors(EBNK-ST-001) | recruiting | Phase 1 / Phase 2 | 83 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07417397 | Adjuvant TACE in HCC With High-risk Recurrence Factors | recruiting | Phase 3 | 442 | Guangxi Medical UniversityOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT03445585 | Biobank for Cholestatic Liver Diseases. | recruiting | — | 9,150 | Mayo ClinicOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07148050 | Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells(IMPACT) | recruiting | Phase 1 | 21 | Seattle Children's HospitalOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07408804 | Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma | recruiting | N/A | 40 | Bangladesh Medical UniversityOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT04690972 | "Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases".(LivMOD) | recruiting | — | 800 | Institut National de la Santé Et de la Recherche Médicale, FranceOTHER_GOV | 1 | Feb 12, 2026 | clinicaltrials |
| NCT06027086 | DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) | recruiting | Phase 1 / Phase 2 | 27 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07223307 | REGULUS: MRI-guided Adaptive SABR for Liver Cancers | recruiting | Phase 2 | 62 | Stanford UniversityOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT07395635 | Phase II Trial of Immunonutrition in Hepatectomy | recruiting | N/A | 100 | Tata Memorial CentreOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT05375370 | Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Monitoring Circulating Tumor DNA(REMNANT) | recruiting | N/A | 150 | University Hospital, RouenOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT07391839 | MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma. | recruiting | Phase 1 | 40 | Suzhou Mednovo Yi Medical Technology Co., Ltd.OTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT07365930 | NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line Therapy(NISTIPS) | recruiting | — | 350 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07378709 | Exploratory Blood-Based Biomarkers in TACE-Treated Hepatocellular Carcinoma(BLOOD-TACE-P) | recruiting | — | 15 | University of BelgradeOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07390838 | A Study of SH009 Injection in Patients With Advanced Solid Tumors. | recruiting | Phase 1 | 150 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07201519 | Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy | recruiting | Phase 2 | 80 | Michael J Cavnar, MDOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT06904170 | Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma(ALICE) | recruiting | Phase 2 / Phase 3 | 196 | UNICANCEROTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT07178587 | Evaluating the roLe of Multiplexed PET Imaging in the Detection and Staging of hepatocellulaR Carcinoma and gAstro-entero-pancreatic Tumors(ELMIRA) | recruiting | N/A | 28 | Nantes University HospitalOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT06313203 | HAI-Floxuridine, or SIRT, Combined With Gemox For Patients With Intra-Hepatic Cholangiocarcinoma Not Amenable to Resection (TOMCAT)(TOMCAT) | recruiting | Phase 2 | 39 | Oslo University HospitalOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT07312162 | Multilevel Determinants of Socioeconomic Disparities in Geographic Late-Stage Hepatocellular Carcinoma Hotspots | recruiting | — | 730 | University of Southern CaliforniaOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07174570 | Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer | recruiting | Phase 2 | 39 | Emory UniversityOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07369505 | Sapu003 in Advanced mTOR-sensitive Solid Tumors | recruiting | Phase 1 | 27 | SAPU NANO (US) LLCINDUSTRY | 1 | Jan 27, 2026 | clinicaltrials |
| NCT05705219 | Development of 3D Multi-Parametric Ultrasound (MPUS) as a Decision Support Tool for Patients(3DMPUS) | recruiting | — | 80 | University of California, San DiegoOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT07348211 | First in Human Study of SIM0610 in Solid Tumors(SIM0610-101) | recruiting | Phase 1 | 260 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07364305 | HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICC(Lalo) | recruiting | Phase 2 | 50 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07364357 | A Phase I Study of CREPT-618 in Locally Advanced HCC | recruiting | Phase 1 | 13 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07039201 | A Study to Evaluate CG-102-12C in Glypican-3 (GPC3) Positive Advanced Hepatocellular Carcinoma (HCC) | recruiting | N/A | 12 | Zhejiang UniversityOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07345247 | RAdiation SEgmentectomy With REsin Microspheres (RASEREM) Study(RASEREM) | recruiting | — | 150 | Ankara UniversityOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT03539822 | Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies(CAMILLA) | recruiting | Phase 1 / Phase 2 | 117 | Anwaar SaeedOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05155189 | A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma | recruiting | Phase 1 | 72 | Zhejiang UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07356531 | Clinical Trial Evaluating the Safety and Efficacy of Tumor Thermosensitive Embolic Agent in Transcatheter Arterial Chemoembolization for Primary Liver Cancer | recruiting | N/A | 216 | JIANGSU SHENMING Medical Technology CO., LtdINDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05366829 | Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma | recruiting | Phase 2 | 35 | Rutgers, The State University of New JerseyOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT06689670 | Needle-based Percutaneous Ablation of Liver Tumors. | recruiting | N/A | 31 | inTumo Therapeutics, Inc.INDUSTRY | 1 | Jan 20, 2026 | clinicaltrials |
| NCT06227728 | Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.(PTC-IMPACT) | recruiting | — | 50 | Gene SolutionsINDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07324824 | Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma | recruiting | Phase 2 | 37 | Sun Yat-sen UniversityOTHER | 1 | Jan 16, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Mar 4, 2026source: clinicaltrials